|[July 04, 2014]
Research and Markets: Global Diabetic Retinopathy Market 2014-2018
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/q86k3s/global_diabetic)
has announced the addition of the "Global
Diabetic Retinopathy Market 2014-2018" report to their offering.
DR is defined as an eye disorder that damages the blood vessels of the
retina. The retina is the light-sensitive inner surface of the eye which
acts as a film for the formation of an image. Long-term diabetes affects
the retina as a high blood glucose level can deteriorate and damage the
tiny blood vessels in the retina.
DR is broadly classified into either non-proliferative DR or
proliferative retinopathy. Treatment for DR is dependent on the stage of
the disease and is directed at trying to slow or stop the progression of
the disease. At present, three types of treatment exist for DR: laser
surgery, injection of corticosteroids or anti-VEGF drugs into the eye,
The aalysts forecast the Global DR market will grow at a CAGR of 6.8
percent over the period 2013-2018.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Pipeline Snapshot
08. Rate of Incidence and Prevalence
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
Abbott Laboratories Ltd.
Alcon Laboratories Inc.
Alimera Sciences Inc.
Ampio Pharmaceuticals Inc.
Antisense Therapeutics Ltd.
BCN (News - Alert) Peptides SA
Bausch & Lomb Inc.
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Ferrosan Holding A/S
Isis Pharmaceuticals Inc.
Novast Laboratories Ltd.
OPKO Health Inc.
Parexel International Corp.
Quark Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Torrent Pharmaceuticals Ltd.
Valeant Pharmaceuticals International Inc.
Vitreoretinal Technologies Inc.
iCo Therapeutics Inc.
For more information visit http://www.researchandmarkets.com/research/q86k3s/global_diabetic
[ Back To TMCnet.com's Homepage ]